Over the years, neuropathologic characterization of autopsy-derived brain tissues has been the cornerstone of research on Guam amyotrophic lateral sclerosis/parkinsonism-dementia complex (ALS/PDC). Within this Core we will provide these services while also serving to provide properly preserved and characterized brain samples to researchers within the Program. Specifically, the Neuropathology-Brain Bank Core will provide supervision and expertise to the Clinical Core to enable the Program to properly obtain autopsy-derived brain specimens with a minimum of post-mortem delay from individuals suffering from ALS/PDC and from Guam residents without a diagnosis of neurodegenerative disorders. The brain specimens obtained by the Clinical Core will be partially dissected on Guam (with half of the brain fixed and half frozen) and sent to the Core for further dissection and characterization. Upon receipt at the Core, each specimen will undergo full neuropathologic evaluation. Besides rendering a neuropathologic diagnosis, the extent and distribution or relevant neuropathologic lesions will be documented and entered into the neuropathology data base. Both frozen and fixed portions of the specimens will be provided to Program researchers. Remaining portions of the brain samples will be preserved in a Brain Bank and serve as a national/international resource for qualified researchers interested in working on the unique and important material.

National Institute of Health (NIH)
National Institute on Aging (NIA)
Research Program Projects (P01)
Project #
Application #
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of California San Diego
La Jolla
United States
Zip Code
Dombroski, Beth A; Galasko, Douglas R; Mata, Ignacio F et al. (2013) C9orf72 hexanucleotide repeat expansion and Guam amyotrophic lateral sclerosis-Parkinsonism-dementia complex. JAMA Neurol 70:742-5
Brunden, Kurt R; Ballatore, Carlo; Lee, Virginia M-Y et al. (2012) Brain-penetrant microtubule-stabilizing compounds as potential therapeutic agents for tauopathies. Biochem Soc Trans 40:661-6
Lee, Virginia M-Y; Brunden, Kurt R; Hutton, Michael et al. (2011) Developing therapeutic approaches to tau, selected kinases, and related neuronal protein targets. Cold Spring Harb Perspect Med 1:a006437
Yu, Chang-En; Bird, Thomas D; Bekris, Lynn M et al. (2010) The spectrum of mutations in progranulin: a collaborative study screening 545 cases of neurodegeneration. Arch Neurol 67:161-70
Brunden, Kurt R; Ballatore, Carlo; Crowe, Alex et al. (2010) Tau-directed drug discovery for Alzheimer's disease and related tauopathies: a focus on tau assembly inhibitors. Exp Neurol 223:304-10
Crowe, Alex; Huang, Wenwei; Ballatore, Carlo et al. (2009) Identification of aminothienopyridazine inhibitors of tau assembly by quantitative high-throughput screening. Biochemistry 48:7732-45
Brunden, Kurt R; Trojanowski, John Q; Lee, Virginia M-Y (2009) Advances in tau-focused drug discovery for Alzheimer's disease and related tauopathies. Nat Rev Drug Discov 8:783-93
Snyder, L R; Cruz-Aguado, R; Sadilek, M et al. (2009) Lack of cerebral bmaa in human cerebral cortex. Neurology 72:1360-1
Choi, Yoonha; Wijsman, Ellen M; Weir, Bruce S (2009) Case-control association testing in the presence of unknown relationships. Genet Epidemiol 33:668-78
Sieh, Weiva; Choi, Yoonha; Chapman, Nicola H et al. (2009) Identification of novel susceptibility loci for Guam neurodegenerative disease: challenges of genome scans in genetic isolates. Hum Mol Genet 18:3725-38

Showing the most recent 10 out of 53 publications